Abstract Introduction:
Introduction
Hemogl obin A1c (HbA1c) is the primary test for the assessment of glycemic control for patients with both type 1 and type 2 diabetes. Both the American and the Canadian Diabetes Association have advocated a treatment target goal for HbA1c of 7% or lower (as close to the nondiabetes range) in order to minimize microvascular and macrovascular complications. 1 If it can be safely achieved, a HbA1c target value of ≤6.0% should be considered.
Analytical imprecision performance goals for HbA1c testing have been set by the National Academy of Clinical Biochemistry at ideally less than 3%. 2 Optimal testing frequency 1 has not been determined, although various expert committees recommend a testing frequency of every 6 months in patients who are meeting treatment goals and more frequently in patients not meeting glycemic goals. Biological variation for HbA1c has been determined to be in the region of 1.7% to 3%. [2] [3] [4] However, there are several reports of a seasonal variation in HbA1c values dating back to 1985 5 when Mortensen found lower HbA1c values in June and July compared to other months. Ishii and colleagues 6 reported a difference of 0.5% between winter and spring/autumn in type 2 diabetes patients in Japan. This change was attributed to increased caloric intake accompanied by decreased physical activity in winter. Also in Japan, Sohmiya and associates 7 found that, in male patients with type 2 diabetes treated with insulin, the HbA1c value was higher in February compared to the nadir in July. They attributed this change to increased insulin resistance. In Taiwan, Chen and coworkers 8 attributed changes in HbA1c to the winter holiday season. In Sweden, Aspenlund 9 showed lower HbA1c values in July with higher values in autumn and winter. He attributed this variation to possible differences in exercise and diet regimens in summer/winter as well as increased insulin sensitivity in the summer. Also in Sweden, Nordfelt and Ludvigsson 10 reported that, in children with type 1 diabetes, there was a seasonal variation with higher values in autumn and winter and lower values in summer and spring. They noted that patients showing larger seasonal variation reported severe hypoglycemia, whereas patients with lower seasonal variation did not show severe hypoglycemia. In the United Kingdom, Carney and colleagues 11 found an increase in June as well as the winter months. In the United States, Tseng and associates 12 noted a difference of 0.22 between summer and winter HbA1c values, with the highest mean HbA1c values in January/February and the lowest HbA1c values in September/October. They also noted that the differences with colder winters had larger winter/ summer variation than those with warmer winters. In contrast, Garde and coworkers 13 from Copenhagen, Denmark, noted that, in healthy women, the HbA1c was higher in September and October and lower in December and January.
All these studies were performed in the northern hemisphere in locations with significant differences in temperatures between winter and summer. We wished to investigate if similar differences existed in the southern hemisphere in a location where there is minimal difference between summer and winter temperatures.
Methods and Materials
The mean maximum temperature for each month and location is shown in Table 1 and was found from meteorological data published by the National Meteorological Institutes (or equivalent) of the country of each location. Two years of HbA1c data were supplied by the participants. Some participants supplied more than two years of data, so data were selected to give maximum overlap between participants. For Singapore, the data were from January 2006 
Results
There appears to be three distinct groupings of mean HbA1c data. Overall, the mean data from Singapore and Melbourne are very close (p = .29) and exhibit the highest mean HbA1c values. Both these locations show a marked drop in HbA1c values during the time of the study, with the drop in Singapore HbA1c occurring in January 2007 and in Melbourne in July 2005. In both cases, the daily quality control values did not indicate a shift in HbA1c values nor was there a change in method. The data from Marshfield and Edmonton show similar means (p = .05), especially after the second June data point, and these are lower than the Singapore/Melbourne means (p < .0001). The mean of the HbA1c data from Calgary is lower than the other two groups (p < .0001). This difference in mean values between the North America and Australasia may be interpreted with the ordering of HbA1c in Singapore and Melbourne occurring mainly in individuals with diabetes having a HbA1c mean of the means of 7.3% (range 7.1% to 7.5%). In Marshfield, the HbA1c mean of means is 7.0% (range 6.8% to 7.2%), and in Edmonton, it is 6.9% (range 6.7% to 7.0%), indicating that HbA1c testing is mainly ordered on individuals with diabetes, with some ordering on nondiabetes patients. The HbA1c mean of the means in Calgary is 6.6% (range 6.4% to 6.8%), which may indicate that HbA1c is ordered on many individuals without diabetes.
For median HbA1c values, there appears to be the same grouping of data as noted for the mean HbA1c data. The Calgary median data (range of 5.9% to 6.3%) are different (p < .001) from the Singapore (range 6.9% to 7.1%), Melbourne (range 7.0% to 7.2%), Edmonton (range 6.4% to 6.7%), and Marshfield data (range 6.5% to 6.8%).
Inspection of the median data from Singapore shows very little variation The maximum HbA1c values in Melbourne is noted in the winter months of June though September, with lower values observed December through March. In Edmonton and Marshfield, the higher values are noted November through March, with lower values June through October. In Calgary, the highest HbA1c value appears in July.
Discussion
The 2-year study reported here is longer than that of 1 year reported in many of the papers on seasonal variation of HbA1c. The finding by Garde and colleagues 13 of higher HbA1c values in a location in the northern hemisphere in September and October with lower values in December and January appears at variance with the reported literature. One possible explanation, although it is a weak argument, is that the subjects in the study were patients without diabetes, while those in other studies were previously identified patients with diabetes. The cyclical pattern is most pronounced with the Marshfield data and may be related to a number of factors, including a stable analysis population of individuals receiving therapy for their diabetes and low analytical variation in the HbA1c method. 14 In previous work it has been noted that a significant proportion of testing in Edmonton and Calgary is performed on asymptomatic individuals as a screen for diabetes and this may skew the data. 15
